References

Cross, Nicholas C. P., Thomas Ernst, Susan Branford, et al. 2023. “European LeukemiaNet Laboratory Recommendations for the Diagnosis and Management of Chronic Myeloid Leukemia.” Leukemia 37 (11): 2150–67. https://doi.org/10.1038/s41375-023-02048-y.

Hochhaus, Andreas, Jianxiang Wang, Dong-Wook Kim, et al. 2024. “Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.” New England Journal of Medicine 391 (10): 885–98. https://doi.org/10.1056/nejmoa2400858.

Jabbour, Elias, Vivian G. Oehler, Paul B. Koller, et al. 2025. “Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib.” JAMA Oncology 11 (1): 28. https://doi.org/10.1001/jamaoncol.2024.5157.

Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.

Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, et al. 2018. “Early Results of Lower Dose Dasatinib (50mg Daily) as Frontline Therapy for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” Cancer 124 (13): 2740–47. https://doi.org/10.1002/cncr.31357.